<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC7392152/results/search/drugs/results.xml">
  <result pre="rather for a general mechanism of viral infection. For instance," exact="chloroquine" post="and hydroxychloroquine have been reported to affect endosomes, the"/>
  <result pre="a general mechanism of viral infection. For instance, chloroquine and" exact="hydroxychloroquine" post="have been reported to affect endosomes, the critical point"/>
  <result pre="antiviral activity [5]. Regardless, in a recent small clinical trial" exact="hydroxychloroquine" post="demonstrated moderate effectiveness in treatment of COVID-19 patients, and"/>
  <result pre="the effect was even more pronounced in co-treatment with antibacterial" exact="azithromycin" post="[6]. This led both drugs to numerous currently ongoing"/>
  <result pre="their potential benefits, mechanisms and safety. The mentioned drugs, chloroquine," exact="hydroxychloroquine" post="and azithromycin, highly accumulate in lysosomes/endosomes and their membranes,"/>
  <result pre="lysosomes). We propose that the antiviral activity of (hydroxy)chloroquine and" exact="azithromycin" post="is shared among all strong lysosomotropic drugs and is"/>
  <result pre="been extensively summarized by Salata et al. [22]. Chloroquine and" exact="amiodarone" post="have so far been amongst the most widely studied"/>
  <result pre="COVID-19 could be their potential anti-inflammatory effects, which was for" exact="azithromycin" post="and chloroquine as well as for a number of"/>
  <result pre="be their potential anti-inflammatory effects, which was for azithromycin and" exact="chloroquine" post="as well as for a number of tool drugs"/>
  <result pre="example antibacterial azithromycin, selective serotonin reuptake inhibitors (SSRI) antidepressants fluoxetine," exact="citalopram" post="and sertraline, as well as well-known antimalarial drug chloroquine."/>
  <result pre="are: promethazine, amodiaquine, chloroquine, mefloquine, tilorone, hydroxychloroquine, arbidol (umifenovir) and" exact="nelfinavir" post="[23] (https://drugvirus.info/). The drugs that passed all applied lysosomotropism"/>
  <result pre="applied lysosomotropism criteria are: azithromycin, promethazine, cyclizine, chloroquine, clemastine, hydroxyzine," exact="rifabutin" post="and vicriviroc, and drugs that do not have data"/>
  <result pre="and thereby preventing infection of the cell. The third antiviral," exact="nelfinavir" post="is a protease inhibitor drug approved for treatment of"/>
  <result pre="primary inclusion criteria. Three of them target respiratory system (bromhexine," exact="ambroxol" post="and formoterol), but should be cautiously assessed at which"/>
  <result pre="tested in numerous ongoing clinical trials on COVID-19, with chloroquine," exact="hydroxychloroquine" post="and azithromycin being most widely studied. FDA has recently"/>
  <result pre="numerous ongoing clinical trials on COVID-19, with chloroquine, hydroxychloroquine and" exact="azithromycin" post="being most widely studied. FDA has recently revoked the"/>
  <result pre="has recently revoked the emergency use authorization (EUA) to use" exact="hydroxychloroquine" post="and chloroquine to treat COVID-19 outside clinical trials due"/>
  <result pre="revoked the emergency use authorization (EUA) to use hydroxychloroquine and" exact="chloroquine" post="to treat COVID-19 outside clinical trials due to the"/>
  <result pre="CADs are also being clinically tested, such as amiodarone, fluoxetine," exact="chlorpromazine" post="and fluvoxamine, but also other drugs with possible CAD"/>
  <result pre="other drugs with possible CAD properties such as imatinib, bromhexine," exact="formoterol" post="[41]. The number of clinical trials and diversity of"/>
  <result pre="the past 50 yearsClin. Microbiol. Rev.29201669574727281742 2Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
  <result pre="the treatment of emerging viral diseasesPharmacol. Res. Perspect.52017e00293 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today’s diseases?Lancet"/>
  <result pre="interaction map reveals targets for drug repurposingNature2020 6GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoréS.ColsonP.ChabrièreE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="endo-/lysosomal system in rat hepatocytesDrug Metab. Dispos.472019495730409837 10TogamiK.ChonoS.MorimotoK.Subcellular distribution of" exact="azithromycin" post="and clarithromycin in rat alveolar macrophages (NR8383) in vitroBiol."/>
  <result pre="in rat hepatocytesDrug Metab. Dispos.472019495730409837 10TogamiK.ChonoS.MorimotoK.Subcellular distribution of azithromycin and" exact="clarithromycin" post="in rat alveolar macrophages (NR8383) in vitroBiol. Pharm. Bull.3620131494149923995662"/>
  <result pre="by decreasing autophagosome-lysosome fusionAutophagy1420181435145529940786 17NujićK.BanjanacM.MunićV.PolančecD.Eraković HaberV.Impairment of lysosomal functions by" exact="azithromycin" post="and chloroquine contributes to anti-inflammatory phenotypeCell. Immunol.2792012788623099154 18LoganR.FunkR.S.AxcellE.KriseJ.P.Drug-drug interactions"/>
  <result pre="autophagosome-lysosome fusionAutophagy1420181435145529940786 17NujićK.BanjanacM.MunićV.PolančecD.Eraković HaberV.Impairment of lysosomal functions by azithromycin and" exact="chloroquine" post="contributes to anti-inflammatory phenotypeCell. Immunol.2792012788623099154 18LoganR.FunkR.S.AxcellE.KriseJ.P.Drug-drug interactions involving lysosomes:"/>
  <result pre="Research Information on Drug-Induced Liver Injury [Online].Available: https://www.ncbi.nlm.nih.gov/books/NBK547852/ [Accessed]2012 37LentiniG.CavalluzziM.M.HabtemariamS.COVID-19," exact="chloroquine" post="repurposing, and cardiac safety concern: chirality might helpMolecules202025 38GriloL.S.CarruptP.A.AbrielH.Stereoselective"/>
  <result pre="stimulated Raman scatteringNat. Chem.6201461462224950332 43Fda. Fda cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
  <result pre="scatteringNat. Chem.6201461462224950332 43Fda. Fda cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
  <result pre="during a five-year period. Incidence and prognosisActa Med. Scand.18219674915016054829 47ChenC.Y.WangF.L.LinC.C.Chronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin."/>
  <result pre="&amp;amp; immunology and dermatologyComprehensiv Med. Chem. II2007 52KrishnaS.WhiteN.J.Pharmacokinetics of quinine," exact="chloroquine" post="and amodiaquine. Clinical implicationsClin. Pharmacokinet.3019962632998983859 53O’maraE.KasserraC.HuddlestoneJ.R.WanY.SoniP.CaceresM.MedlockM.MorrisonR.DevinskyO.Effect of vicriviroc on"/>
  <result pre="K+ channelJ. Mol. Cell. Cardiol.40200610711816288909 55SchranH.F.PetrykL.ChangC.T.O’connorR.GelbertM.B.The pharmacokinetics and bioavailability of" exact="clemastine" post="and phenylpropanolamine in single-component and combination formulationsJ. Clin. Pharmacol.3619969119228930778"/>
  <result pre="single-component and combination formulationsJ. Clin. Pharmacol.3619969119228930778 56SchrezenmeierE.DörnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.16202015516632034323 57ShiJ.MontayG.BhargavaV.O.Clinical pharmacokinetics"/>
  <result pre="first ketolide antibacterialClin. Pharmacokinet.44200591593416122280 58StanatS.J.CarltonC.G.CrumbW.J.Jr.AgrawalK.C.ClarksonC.W.Characterization of the inhibitory effects of" exact="erythromycin" post="and clarithromycin on the HERG potassium channelMol. Cell. Biochem.25420031714674677"/>
  <result pre="antibacterialClin. Pharmacokinet.44200591593416122280 58StanatS.J.CarltonC.G.CrumbW.J.Jr.AgrawalK.C.ClarksonC.W.Characterization of the inhibitory effects of erythromycin and" exact="clarithromycin" post="on the HERG potassium channelMol. Cell. Biochem.25420031714674677 59TaylorG.HoustonJ.B.ShafferJ.MawerG.Pharmacokinetics of"/>
  <result pre="clarithromycin on the HERG potassium channelMol. Cell. Biochem.25420031714674677 59TaylorG.HoustonJ.B.ShafferJ.MawerG.Pharmacokinetics of" exact="promethazine" post="and its sulphoxide metabolite after intravenous and oral administration"/>
  <result pre="Drug Saf.4200542143115934850 61Van HaarstA.D.Van’ T KloosterG.A.Van GervenJ.M.SchoemakerR.C.Van OeneJ.C.BurggraafJ.CoeneM.C.CohenA.F.The influence of" exact="cisapride" post="and clarithromycin on QT intervals in healthy volunteersClin. Pharmacol."/>
  <result pre="61Van HaarstA.D.Van’ T KloosterG.A.Van GervenJ.M.SchoemakerR.C.Van OeneJ.C.BurggraafJ.CoeneM.C.CohenA.F.The influence of cisapride and" exact="clarithromycin" post="on QT intervals in healthy volunteersClin. Pharmacol. Ther.6419985425469834046 62WalkerR.B.KanferI.Pharmacokinetics"/>
  <result pre="on QT intervals in healthy volunteersClin. Pharmacol. Ther.6419985425469834046 62WalkerR.B.KanferI.Pharmacokinetics of" exact="cyclizine" post="following intravenous administration to human volunteersEur. J. Pharm. Sci.1996"/>
 </snippets>
</snippetsTree>
